Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues to Demonstrate Positive Trends in the Week 48 Analysis View HTML
Toggle Summary Anthera Pharmaceuticals Announces Participation at Upcoming Healthcare Conferences View HTML
Toggle Summary Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients with Active Systemic Lupus Erythematosus View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results View HTML
Toggle Summary Anthera Announces That Data From the Phase 2 BRIGHT-SC Study Has Been Accepted as a Late Breaking Abstract at the ASN Kidney Week 2016 Annual Meeting View HTML
Toggle Summary Anthera Pharmaceuticals to Provide Business Update and Report 2016 Third Quarter Financial Results on November 4 View HTML
Toggle Summary Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital View HTML
Toggle Summary Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer View HTML
Toggle Summary Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™ View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results View HTML